Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBITDA (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed EBITDA for 15 consecutive years, with -$110.0 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA fell 3.18% year-over-year to -$110.0 million; the TTM value through Mar 2026 reached -$475.5 million, down 8.0%, while the annual FY2025 figure was -$472.1 million, 10.9% down from the prior year.
  • EBITDA hit -$110.0 million in Q1 2026 for Agios Pharmaceuticals, up from -$121.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$90.6 million in Q1 2023 and bottomed at -$127.1 million in Q2 2025.
  • Average EBITDA over 5 years is -$105.2 million, with a median of -$102.8 million recorded in 2024.
  • Year-over-year, EBITDA crashed 105.4% in 2022 and then grew 10.41% in 2023.
  • Agios Pharmaceuticals' EBITDA stood at -$99.2 million in 2022, then fell by 7.16% to -$106.3 million in 2023, then decreased by 17.65% to -$125.0 million in 2024, then grew by 2.77% to -$121.6 million in 2025, then increased by 9.5% to -$110.0 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$110.0 million, -$121.6 million, and -$116.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.